Our molecular understanding of glioma has undergone a sea change over the last decade. In this review, we discuss two recent articles that employed whole genome sequencing to subclassify gliomas vis-à-vis known molecular alterations. We further discuss the relevance of these findings vis-à-vis current treatment paradigms.
Keywords: 1p/19q; glioblastoma; glioma; idh; neuro-oncology; precision medicine; tert.